HCW Biologics Inc. (NASDAQ:HCWB) Short Interest Update

HCW Biologics Inc. (NASDAQ:HCWB) saw a significant increase in short interest during the month of January. As of January 30th, there was short interest totaling 53,964 shares, an increase of 151.7% from the January 15th total of 21,438 shares. Approximately 2.9% of the shares of the company are sold short. Based on an average daily trading volume, of 93,084 shares, the days-to-cover ratio is presently 0.6 days. Based on an average daily trading volume, of 93,084 shares, the days-to-cover ratio is presently 0.6 days. Approximately 2.9% of the shares of the company are sold short.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of HCW Biologics in a report on Thursday, January 22nd. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $35.00.

HCW Biologics Price Performance

Shares of HCWB stock traded down $0.16 during trading hours on Thursday, reaching $0.83. 98,379 shares of the company traded hands, compared to its average volume of 67,584. The firm has a 50-day moving average price of $1.37 and a 200 day moving average price of $2.98. The company has a market cap of $2.73 million, a P/E ratio of -0.07 and a beta of 0.72. HCW Biologics has a 12-month low of $0.83 and a 12-month high of $17.80.

HCW Biologics (NASDAQ:HCWB) last released its earnings results on Friday, November 14th. The company reported ($2.02) EPS for the quarter, missing analysts’ consensus estimates of $1.58 by ($3.60). The business had revenue of $0.00 million for the quarter, compared to the consensus estimate of $7.00 million.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in HCW Biologics stock. Golden State Wealth Management LLC bought a new position in HCW Biologics Inc. (NASDAQ:HCWB) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 10,000 shares of the company’s stock, valued at approximately $40,000. Golden State Wealth Management LLC owned 0.69% of HCW Biologics as of its most recent filing with the SEC. 2.96% of the stock is currently owned by institutional investors.

About HCW Biologics

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.